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Background: Surgical microvascular decompression (MVD) is the curative treatment for hemifacial spasm (HFS).
Monitoring MVD by recording the lateral spread response (LSR) intraoperatively can predict a successful clinical
outcome. However, the rate of the LSR varies between trials, and the reason for this variation is unclear. The aim of
our trial is to evaluate the rate of the LSR after intubation following treatment with succinylcholine, vecuronium, or
no muscle relaxant.
Methods and design: This trial is a prospective randomised controlled trial of 96 patients with HFS (ASA status I or
II) undergoing MVD under general anaesthesia. Patients are randomised to receive succinylcholine, vecuronium, or
no muscle relaxant before intubation. Intraoperative LSR will be recorded until dural opening. The primary outcome
of this study is the rate of the LSR, and the secondary outcomes are post-intubation pharyngolaryngeal symptoms,
the rate of difficult intubations, the rate of adverse haemodynamic events and the relationship between the
measurement of LSR or not, and clinical success rates at 30 days after surgery.
Discussion: This study aims to evaluate the impact of muscle relaxants on the rate of the LSR, and the study may
provide evidence supporting the use of muscle relaxants before intubation in patients with HFS undergoing MVD
surgery.
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Primary hemifacial spasm (HFS) is a disorder that causes
frequent involuntary contractions in the muscles on one
side of the face, due to a blood vessel compressing the
nerve at its root exit zone (REZ) from the brainstem [1].
Numerous prospective and retrospective case series have
confirmed the efficacy of microvascular decompression
(MVD) of the facial nerve in patients with HFS with low
rates of symptom recurrence and transient complica-
tions [1].
In 1985, Møller and Jannetta [2] showed that in HFS,
stimulation of one branch of the facial nerve activates fa-
cial muscles innervated by another branch, thereby pro-
ducing abnormal muscle responses (AMR). These AMR
are known as the lateral spread response (LSR) and can
be recorded from one muscle innervated by the superior
branch of the facial nerve when the inferior branch is
stimulated or vice versa (Figure 1). Due to the fact that
the LSR disappears instantly in most patients when the
offending vessel is moved off the facial nerve, monitor-
ing the AMR can guide the surgeon during MVD, which
results in a better post-operative outcome [3]. Although
the practical value of the LSR disappearance as a method
to evaluate MVD efficacy is still controversial [4,5], in
most cases, LSR monitoring is an effective tool to pre-
dict outcome after MVD for HFS [6].
However, an accurate estimate of the LSR rate is not
yet known; the rate varies from 75% to 100% [7-14] be-
tween trials. Patients without the LSR would not benefit
from this technology.
The reasons why the LSR is not detectable in some
patients are unclear. Kong et al. hypothesised that the
absence of the LSR was associated with the dosage of
the muscle relaxant or the insertion site of the needle
[11]; other researchers hypothesised that it was related
to a process of denervation-reinnervation caused by pre-
ceding botulinum toxin injections [9]. However, theseFigure 1 Schematic illustration shows the stimulation and
recording electrodes.hypotheses have not yet been verified. While consulting
the literature, we found that the muscle relaxants used
in the various trials differed, which might be an import-
ant factor associated with the LSR rate. In most studies,
short-acting muscle relaxants were used [1,7,9,10,13,15].
Sekula et al. [6] indicated that non-depolarising muscle
relaxants should be used. While other studies described
that muscle relaxants were used for intubation [4,14],
they did not identify which muscle relaxants were used.
Among the studies in the literature, several studies
[11,13,16] performed the train of four (TOF) test to
measure the degree of neuromuscular blockade and
maintained the ratio at a level of 0.5 to 0.75.
Succinylcholine
Succinylcholine (Sch) is an ultra-short-acting depolaris-
ing neuromuscular blocking agent (NMBA). This agent
inhibits the action of acetylcholine at the neuromuscular
junction. At a dose of 1 mg/kg, the onset time of Sch is
4 seconds; the time to 25% recovery is 10 minutes, and
the time to 95% recovery is 12 to 15 minutes [17].
Vecuronium
Vecuronium is an intermediate-acting non-depolarising
neuromuscular blocking agent. This agent acts by
competing for cholinergic receptors at the motor end-
plate. At a dose of 0.1 mg/kg, the onset time of vecur-
onium is 2.3 minutes; the time to 25% recovery is 45
to 60 minutes, and the time to 95% recovery is 60 to
80 minutes [17].
The primary objective of this study is to evaluate the
rate of LSR in HFS patients undergoing MVD under
general anaesthesia with tracheal intubation, with suc-
cinylcholine, vecuronium, or no muscle relaxant. The
secondary objectives are post-intubation pharyngolaryn-
geal symptoms, ease of intubation, haemodynamic
responses and the relationship between the measure-
ment of LSR or not, and clinical success.
Methods
This is a randomised controlled study comparing the
LSR rate in HFS patients undergoing MVD under gen-
eral anaesthesia with tracheal intubation, and prior treat-
ment with succinylcholine, vecuronium, or no muscle
relaxant.
This study is a three-arm, randomised controlled trial.
Participants fulfilling eligibility criteria were selected. En-
rolled participants were randomly allocated to three par-
allel groups: the Succinylcholine, Vecuronium, or No
Muscle Relaxant.
Inclusion and exclusion criteria
Inclusion criteria: adult patients (American Society of
Anesthesia (ASA) status I or II) (Table 1) [18] diagnosed
Table 1 ASA physical status classification system
Classification Physical status
1 A normal healthy patient.
2 A patient with mild systemic disease.
3 A patient with severe systemic disease.
4 A patient with severe systemic disease that
is a constant threat to life.
5 Amoribundpatient who is not expected
to survive without the operation.
6 A patient declared brain-dead whose organs
are being removed for donor purposes.
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anaesthesia will be enrolled.
Exclusion criteria: patients with: HFS secondary to
aneurysms, tumours, or cysts; factors predictive of a diffi-
cult intubation; a BMI above 30 kg/m2; a history of allergy
to muscle relaxants. Patients reporting any preoperative
sore throat or hoarseness at history taking will be
excluded.
All consenting patients fulfilling the inclusion cri-
teria are randomised into three groups in a 1:1:1 ratio
(G1, the Succinylcholine group; G2, the Vecuronium
group; G3, the No Muscle Relaxant group). The flow
chart of the present trial is shown in Figure 2.Figure 2 Trial flow chart. *Rate of the LSR. **Post-intubation pharyngolar
***Post-surgical symptoms of hemifacial spasm.Patient demographic data will be collected for age, sex,
duration of symptoms, location, history of botulinum
toxin injections prior to MVD, and offending vessel.
Blinding: double blinding is not possible because of
the muscle fasciculation caused by succinylcholine [19].
Outcome assessors will be blinded.Randomisation
Block randomisation was performed using a computer-
generated list containing a sequence of letters, G1 refer-
ring to the Succinylcholine group, G2 referring to the
Vecuronium group and G3 referring to the No Muscle
Relaxant group. Block sizes vary with three, six or nine let-
ters. Allocations were concealed in opaque, sealed envel-
opes. The envelope contains a number that is concealed
as to the allocation. The list will be generated and kept by
a person not involved in the study in the operating room.
The number of envelopes matches the number of patients
ready for the randomisation and follows the sequential
numbers on the generated list.Outcome measures
The primary outcome is the intraoperative LSR rate.
All patients undergo orotracheal intubation in the su-
pine position with the head and neck in neutral positions.yngeal symptoms, ease of intubation and haemodynamic responses.
Table 2 IDS Score
Parameter Score
Number of attempts > 1 N1
Number of operators > 1 N2
Number of alternative techniques N3
Cormack grade N4
Lifting force required
Normal N5 = 0
Increased N5 = 1
Laryngeal pressure
Not applied N6 = 0
Applied N6 = 1
Vocal cord mobility
Abduction N7 = 0
Adduction N7 = 1
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genation through a face mask for 4 min, anaesthesia is
induced with propofol (target-controlled infusion (TCI) 4
to 6 μg/ml), sufentanil 0.3 to 0.5 μg/kg, midazolam 2 to
3 mg, and either succinylcholine 1 to 1.5 mg/kg (G1),
vecuronium 0.1 mg/kg (G2), or no muscle relaxant (G3).
Tracheal intubation is attempted 90 s after the administra-
tion. Intubation is always performed by an experienced
anaesthetist using endotracheal tubes (Lo-Contour;
Mallinckrodt, Athlone, Ireland) with an internal diameter
of 7.0 mm for female patients and 7.5 mm for male
patients. Mechanical ventilation is controlled, with end-
tidal carbon dioxide being maintained at 30 to 40 mm Hg
[17]. Anaesthesia is maintained using total intravenous an-
aesthesia (TIVA) with propofol and sufentanil.
After intubation, a bipolar subdermal needle electrode is
inserted subcutaneously over the zygomatic branches
of the facial nerve on the side of HFS with a 0.5 to
1 cm spacing. Another bipolar needle electrode is
placed in the mentalis muscles for LSR recordings.
Electrical stimulation, consisting of square-wave
pulses (intensity: 5 to 15 mA; duration: 0.2 ms) and
electromyographic (EMG) recordings, are filtered
through a 30 Hz to 3 kHz band pass (gain: 500 mV/
division; analysis time: 50 ms) (Axon Epoch 2000 Sys-
tems, Hauppauge, NY, USA). To avoid nerve fatigue,
the LSR is evoked with a 2 min interval until dural
opening.
The LSR is defined as the EMG response recorded from
the mentalis muscle by electrical stimulation of the zygo-
matic branch of the facial nerve, usually with a latency of
approximately 10 ms.
The secondary outcomes for this study are post-
intubation pharyngolaryngeal symptoms, ease of intub-
ation, haemodynamic responses, clinical success rates and
its relationship to the measurement of LSR or not at
30 days after surgery, as described below:
1. Post-intubation pharyngolaryngeal symptoms are
defined as hoarse or sore throat 24 h after
extubation. The severity of the complaint is
assessed on a 101-point numerical rating scale
(0 = no discomfort, 100 = extreme discomfort).
2. The rate of difficult intubations is defined as an
IDS score >5. The IDS (Table 2) is the sum of the
seven following variables: number of tracheal
intubation attempts, number of operators who
attempted intubation, number of alternative
techniques used, glottic exposure (as defined by
the Cormack and Lehane classification [20]),
intensity of lifting force (normal or increased)
applied during laryngoscopy, necessity for external
laryngeal manipulation, and position of the vocal
cords (Table 2) [21].3. The rate of adverse haemodynamic events is defined
as hypotension and bradycardia and the need to
administer ephedrine or atropine.
4. Clinical success is defined as HFS relief at 30 days
after surgery.
Sample size calculation
We performed a pilot study of the LSR rate (following
the same protocol as the proposed study) before writing
the protocol. According to the results of our preliminary
study, the Vecuronium group percentage is assumed to
be 60%, the Succinylcholine group percentage is
assumed to be 70%, and the No Muscle Relaxant group
percentage is 100%. Effect size is assumed 0.4 corre-
sponding to our preliminary result. A sample size of 27
patients for each study group with an allocation ratio of
1:1:1 for a total of 81 patients is required to achieve 90%
power (alpha at 0.05) to detect a difference among the
groups in the primary end-point variable (LSR rate)
(G*Power 3.1.2 software). Allowing for a drop-out rate
of 15% per group, we decided to recruit 96 participants.
Statistical analysis
Double data entry will be done by assistants not partici-
pating in the study. Baseline characteristics will be
described and compared for all three groups. All main
analyses were based on the intention-to-treat patients.
The primary statistical analysis is performed at the end
of the surgery. All three group comparisons will be con-
ducted. LSR rates will be compared using the chi-square
test and RR is assumed for the calculation. All the di-
chotomous (secondary) outcomes will be compared be-
tween the three treatment groups using the chi square
(or Fisher’s exact) test. Continuous (secondary) outcome
Fang et al. Trials 2012, 13:160 Page 5 of 6
http://www.trialsjournal.com/content/13/1/160of the severity of the complaint will be compared using
one-way ANOVA.
Statistical analyses will be carried out using the SPSS
software (SPSS 18.0, Chicago, IL, USA). A P <0.05 will
be considered statistically significant.
Treatment discontinuation
If intubating conditions are unsatisfactory due to poor
muscle relaxation, the second anaesthetist in attendance
could administer succinylcholine (1 mg/kg) to patients
in the No Muscle Relaxant group, but all patients rando-
mized need to be included in the analyses.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki (2008 version) [22].
The Medical Ethics Committee of the West China
Hospital, Sichuan University approved the protocol be-
fore start of the trial (6 Sep, 2011 Number 77; President
Prof. Zeng Yong).
Discussion
In the present study, we chose succinylcholine and
vecuronium because they are the most frequently used
neuromuscular blockers and are ultra-short-acting depo-
larising and intermediate-acting non-depolarising muscle
relaxants, respectively. We did not choose rocuronium
(the most rapid-onset non-depolarising relaxant) be-
cause it should be kept in the refrigerator at 2 to 8
degrees, which is unavailable in our operating room. We
monitor the LSR from intubation to the dural opening,
not during the whole surgery. Because the outflow of
cerebrospinal fluid also causes a temporary shift in the
neurovascular relationship equivalent to decompression,
the LSR may disappear after the drainage of cerebro-
spinal fluid [7,9,13]. Anaesthesia is maintained using
total intravenous anaesthesia (TIVA), because inhalation
anaesthetics enhance the effect of muscle relaxants [23].
The mechanism of the LSR is controversial and may
be a result of pulsatile compression at the REZ of the fa-
cial nerve [24]. The LSR has been related to cross-
transmission (ephaptic transmission) of antidromic ac-
tivity that occurs at a central site in the facial nucleus
[25], but recently, Møller et al. has demonstrated that
the abnormal responses are due to hyperactivity of the
facial motor nucleus [26].
An important limitation that must be noted is that we
do not routinely perform the TOF to measure the degree
of the muscle relaxation. We plan to perform the TOF
of the orbicularis oculi to study the relationship between
the degree of muscle relaxation and the LSR in further
studies.
To the best of our knowledge, this trial is the first at-
tempt to investigate the LSR rate and the impact ofmuscle relaxants on the LSR. The results of this trial will
have a major impact on the induction regimen of anaes-
thesia in patients with HFS undergoing MVD.
Trial status
The trial was started in September 2011. To date, more
than 30 patients have been included.
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